公开(公告)号：US20240342196A1

公开(公告)日：2024-10-17

申请号：US18634143

申请日：2024-04-12

申请人： The UAB Research Foundation ,  The Regents of the University of California

发明人： Sansanka Ramanadham ,  Tayleur D. White ,  Bruce Hammock ,  Sung Hee Hwang

IPC分类号： A61K31/64 ,  A61K31/202 ,  A61K31/4468 ,  A61P3/10

CPC分类号： A61K31/64 ,  A61K31/202 ,  A61K31/4468 ,  A61P3/10

摘要： Disclosed herein are lipid signaling pathways that can be targeted to prevent or delay the onset of type 1 diabetes (T1D). In particular, disclosed herein a pathway that can be modulated by a chemical inhibitor. Utilizing this inhibitor, evidence was generated suggesting that it is beneficial in reducing the incidence of T1D.

公开(公告)号：US20240336562A1

公开(公告)日：2024-10-10

申请号：US18264949

申请日：2022-02-10

申请人： Hangzhou Innogate Pharma Co., Ltd.

发明人： Hancheng ZHANG ,  Wei JIA ,  Congcong CAI

IPC分类号： C07C317/26 ,  A61K31/64 ,  C07D205/06 ,  C07D211/96 ,  C07D213/64 ,  C07D231/18 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12

CPC分类号： C07C317/26 ,  A61K31/64 ,  C07D205/06 ,  C07D211/96 ,  C07D213/64 ,  C07D231/18 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12

摘要： The present invention provides a compound serving as an NLRP3 inhibitor. Specifically, the present invention provides a compound having a structure shown in the following formula (I), or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, and solvate thereof. The compound can be used for treating or preventing diseases or disorders associated with the activity or expression level of NLRP3.

公开(公告)号：US20240285654A1

公开(公告)日：2024-08-29

申请号：US18635765

申请日：2024-04-15

申请人： REMEDY PHARMACEUTICALS, INC.

发明人： Kenny K. TRAN ,  Deirdre LOWE ,  Rupa Rishikesh SAWANT ,  Haihong CHEN ,  Yiqing LIN

IPC分类号： A61K31/64 ,  A61K9/00 ,  A61K9/19 ,  A61K47/18 ,  A61K47/26

CPC分类号： A61K31/64 ,  A61K9/0019 ,  A61K9/19 ,  A61K47/18 ,  A61K47/26

摘要： Methods and formulations for minimizing or avoiding the sorption of glyburide to surfaces of delivery tubing, filters, bags, and other containers and materials, thereby storing and delivering a more stable product, delivering a predictable and accurate dose of glyburide, while minimizing impurities, avoiding drug waste, reducing cost, and significantly reducing the amount of dosing solution that must be infused into the patient.

公开(公告)号：US12048677B2

公开(公告)日：2024-07-30

申请号：US16784452

申请日：2020-02-07

申请人： CEVA SANTE ANIMALE

发明人： Beatrice Besche-Barbazanges ,  Jerome Guyonnet

IPC分类号： A61K31/64 ,  A61K31/137 ,  A61P9/00 ,  A61P9/04 ,  A61K9/20 ,  A61K45/06

CPC分类号： A61K31/137 ,  A61P9/00

摘要： The invention relates to novel veterinary compositions comprising torasemide or a pharmaceutically acceptable salt thereof and administered in domestic animals according to a predetermined dosage for symptomatic treatment of pulmonary edema associated with heart failure.

公开(公告)号：US20230201225A1

公开(公告)日：2023-06-29

申请号：US18118209

申请日：2023-03-07

申请人： REPRISE PHARMACEUTICALS, INC.

发明人： Marc J. Simard

IPC分类号： A61K31/64 ,  A61K31/225

CPC分类号： A61K31/64 ,  A61K31/225

摘要： The present invention provides methods treating multiple sclerosis (MS) in a patient in need of treatment thereof. The methods comprise co-administering to the patient a fumarate or pharmaceutical acceptable salt thereof, and at least one sulfonylurea or pharmaceutical acceptable salt thereof, where the amount of the fumarate is administered at a dose lower than the therapeutically effective dose if the fumarate is administered alone.

公开(公告)号：US20230110554A1

公开(公告)日：2023-04-13

申请号：US17911233

申请日：2021-03-12

申请人： CONSTANT THERAPEUTICS LLC

发明人： Richard FRANKLIN

IPC分类号： A61K38/08 ,  A61K31/64 ,  A61P31/14 ,  A61P11/00

摘要： The present invention provides methods and compositions for treating lung disease in individuals as a complication of infection by pathogens, including coronaviruses. The present invention is based on the use of an angiotensin (1-7) peptide or angiotensin (1-7) receptor agonist in treating patients infected with coronaviruses including COVID-19, SARS, MERS and others. In some embodiments, the angiotensin (1-7) peptide or angiotensin (1-7) receptor agonist is used to treat lung diseases including but not limited to bronchitis, pneumonia, asthma, pulmonary fibrosis and acute respiratory distress syndrome.

公开(公告)号：US11517577B2

公开(公告)日：2022-12-06

申请号：US17262915

申请日：2019-07-30

申请人： NZP UK LIMITED ,  THE UNIVERSITY OF SOUTHAMPTON

发明人： Alexander Charles Weymouth-Wilson ,  Gemma Packer ,  Bruno Jan Pol Linclau ,  Dannielle Kydd-Sinclair ,  Kimberly Ann Watson

IPC分类号： A61K31/64 ,  A61P1/16 ,  A61K31/575 ,  C07J41/00

摘要： The invention relates to compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic steatohepatitis (NASH); primary biliary cirrhosis; primary sclerosing cholangitis; biliary atresia; cholestatic liver disease; hepatitis C infection; alcoholic liver disease; fibrosis; and liver damage arising from fibrosis.

公开(公告)号：US20220280514A1

公开(公告)日：2022-09-08

申请号：US17596502

申请日：2020-06-08

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Alan S. VERKMAN

IPC分类号： A61K31/519 ,  A61K31/426 ,  A61K31/165 ,  A61K31/64 ,  A61K31/44 ,  A61K31/196 ,  A61K31/785 ,  A61K31/787 ,  A61K31/575 ,  A61K31/451 ,  A61K31/417 ,  A61K31/437 ,  A61P1/12

摘要： The disclosure is directed to methods of treating bile acid diarrhea by administering a CFTR chloride channel inhibitor (CFTR-CCI). The CFTR chloride channel inhibitor can be benzopyrimido-pyrrolo-oxazine-dione-CFTR-CCI (e.g., BPO-27), a PPQ-CFTR-CCI, a thiazolidinone-CFTR-CCI, or a glycine hydra-zide-CFTR-CCI.

公开(公告)号：US20220193096A1

公开(公告)日：2022-06-23

申请号：US17645239

申请日：2021-12-20

申请人： University of Maryland, Baltimore ,  The United State of America as Represented by the Department Affairs

发明人： J. Marc Simard

IPC分类号： A61K31/64 ,  A61K31/00 ,  A61K31/195 ,  A61K31/198 ,  A61K31/4453 ,  A61K31/454 ,  A61K45/06 ,  A61K31/451

摘要： Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury. In particular, the methods and compositions are inhibitors of a particular NCCa-ATP channel and include, for example, inhibitors of SUR1 and/or inhibitors of TRPM4. Kits for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury, are also provided. The present invention also concerns treatment and/or prevention of intraventricular hemorrhage in infants, including premature infants utilizing one or more inhibitors of the channel is provided to the infant, for example to brain cells of the infant.

公开(公告)号：US20220184070A1

公开(公告)日：2022-06-16

申请号：US17598122

申请日：2020-03-25

申请人： The George Institute for Global Health

发明人： Anthony RODGERS ,  Stephen MACMAHON

IPC分类号： A61K31/4985 ,  A61K31/155 ,  A61K31/64 ,  A61P3/10

摘要： Pharmaceutical compositions useful in the treatment of metabolic disorders including diabetes, the compositions comprising a) a dipeptidyl peptidase IV (DPP IV) inhibitor such as sitagliptin, b) a biguanide such as metformin, and c) a sulfonylurea such as glimepiride, wherein each one of the DPPIV inhibitor, biguanide and sulfonylurea are at a dose that is at about 20-75% of the lowest diabetes therapeutic dose (LDTD).